Fas expression in memory CD8+ T cell subsets augments cellular differentiation and effector function
Memory CD8 + T cells (T Mem ) have the capacity to provide lifelong host protection against intracellular pathogens and cancer. Despite phenotypic and functional heterogeneity among T Mem , the expression of Fasa tumor necrosis family receptor (TNFR) superfamily member conventionally known as a death receptoris held in common among all T Mem subsets across multiple species. As Fas has been shown to mediate non-death signaling in other cell types, we set out to elucidate the role of Fas signaling in defined T Mem subsets, including T stem cell memory (T SCM ), T central memory (T CM ), and T effector memory (T EM ). We found that augmenting Fas signaling in stimulated T SCM using an oligomerized form of its ligand FasL resulted in augmented cellular differentiation and a loss in IL-2 secretion capacity. Conversely, antibody blockade (anti-FasL) of Fas signaling in T CM retarded cellular differentiation both phenotypically and functionally. To genetically disentangle the pro-apoptotic and differentiation signals from Fas, we made use of a mutant Fas lacking a transmembrane cysteine residue (FasC194V) that is unable to undergo S-palmitoylation and aggregate efficiently in lipid rafts. Using transgenic mice expressing this C194V Fas construct on a Fas-deficient lpr background, we found that FasC194V T Mem can still undergo cellular differentiation in the absence of death signaling. In vivo, T Mem expanded with anti-FasL showed greater expansion, ontarget immunity and withheld differentiation. Additionally, in a relevant syngeneic model of current human T cell immunotherapy, T Mem cells expanded with anti-FasL and genetically engineered with an anti-CD19 chimeric antigen receptor (CAR) exhibited enhanced CAR expression, reduced differentiation, and augmented anti-lymphoma activity compared to controls. These studies demonstrate that Fas signaling promotes not only cell death but also T Mem effector differentiation, a finding that has implications for the design and execution of T cell-based immunotherapies in patients with cancer or infectious disease. 
